Ifp Advisors, Inc Revance Therapeutics, Inc. Transaction History

Ifp Advisors, Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	SELL	$24.7 - $37.61 $49,400 - $75,220	-2,000 Reduced 96.39%	75 $1,000
Q1 2023 Apr 18, 2023	BUY	$18.36 - $35.27 $36,720 - $70,540	2,000 Added 2666.67%	2,075 $66,000
Q4 2022 Feb 07, 2023	SELL	$18.32 - $30.66 $164 - $275	-9 Reduced 10.71%	75 $2,000
Q2 2022 Sep 06, 2022	BUY	$11.52 - $20.4 $967 - $1,713	84 New	84 $3,000
Q2 2022 Aug 12, 2022	SELL	$11.52 - $20.4 $967 - $1,713	-84 Closed	0 $0
Q1 2022 Aug 08, 2022	BUY	$12.36 - $20.31 $111 - $182	9 Added 12.0%	84 $1,000
Q4 2021 Jan 12, 2022	BUY	$12.46 - $27.87 $934 - $2,090	75 New	75 $1,000
Q3 2017 Oct 30, 2017	SELL	$22.55 - $28.1 $28,187 - $35,125	-1,250 Closed	0 $0
Q2 2017 Jun 03, 2019	BUY	N/A	250 Added 25.0%	1,250 $33,000
Q1 2017 Jun 03, 2019	BUY	N/A	1,000	1,000 $21,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.